Inhibition of the function of pulmonary surfactant in the alveolar space is
an important element of the pathophysiology of many lung diseases, includi
ng meconium aspiration syndrome, pneumonia and acute respiratory distress s
yndrome. The known mechanisms by which surfactant dysfunction occurs are (a
) competitive inhibition of phospholipid entry into the surface monolayer (
e.g. by plasma proteins), and (b) infiltration and destabilization of the s
urface film by extraneous lipids (e.g. meconium-derived free fatty acids).
Recent data suggest that addition of non-ionic polymers such as dextran and
polyethylene glycol to surfactant mixtures may significantly improve resis
tance to inhibition. Polymers have been found to neutralize the effects of
several different inhibitors, and can produce near-complete restoration of
surfactant function. The anti-inhibitory properties of polymers, and their
possible role as an adjunct to surfactant therapy, deserve further explorat
ion.